Experts discuss the use of checkpoint inhibitors in the first and second line for advanced urothelial carcinoma as well as future directions.
This activity is intended for oncologists, urologists, emergency department physicians, and other healthcare professionals who treat patients with bladder cancer.
The goal of this activity is to increase understanding in the latest advances in immunotherapy for the treatment of patients with advanced bladder cancer.
- Have increased knowledge regarding the current role for immune checkpoint inhibitors (ICIs) in the treatment of advanced urothelial carcinoma (UC).
- Have increased knowledge regarding novel ICIs and novel combination trials in advanced UC.
- Have greater competence related to incorporating emerging data into clinical practice when managing patients with advanced UC.
Approximate Time to Complete: 60 minutes
Credit Available: April 8, 2020 - April 8, 2021
Developed through a partnership between SITC and Medscape.
Additional Resources for Clinicans from SITC:
"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma" (Published August 15, 2017)